Accentia autoimmune, cancer news

Accentia and its Biovest International Inc. (OTCQB:BTVI, Tampa Fla.) subsidiary emerged from Chapter 11 bankruptcy after filing in Nov. 2008. Under the plan, shareholders will retain their shares. Accentia's Revimmune cyclophosphamide has completed Phase II testing to treat multiple sclerosis. Accentia has exclusive, worldwide rights to the ultra-high intensity, short course of an IV formulation of cyclophosphamide to treat autoimmune indications from Revimmune LLC (Tampa, Fla.) under a 2007 deal. ...